Can Artesunate, an antimalarial drug, provide an effective and affordable treatment for Bowel Cancer By Professor Sanjeev Krishna

108.5% funded

£50,000.00 the goal

Closed

£54,247.66 pledged so far from 327 backers
View this project's backers >

Latest Backers

  • John Carty : £50.00
  • Jerry Young : £500.00
  • lucy Fairley : £100.00
  • Anonymous : £1,000.00
  • Michael Gee : £25.00
  • Ming Ng : £50.00
  • Louisa Ponnampalam : £20.00
  • Helen Brownen : £23.82
  • Chris Barker : £200.00
  • Anonymous : £50.00
  • Peter Nunn : £25.00
  • Anonymous : £10.00
  • Anonymous : £20.00
  • Petra Dunai : £20.00
  • PRITI PATEL : £201.00
  • ADURSH BALI : £500.00
  • Anonymous : £10.00
  • Melanie Monteiro : £10.00
  • Caroline Finlayson : £100.00
  • Anonymous : £100.00
  • Viv Armstrong-MacDonnell : £100.00
  • Anonymous : £50.00
  • Anonymous : £100.00
  • Carol LOCKE : £100.00
  • Jason Dove : £10.00
  • Peter Nunn : £25.00
  • Sanjeev Krishna : £1,000.00
  • Anonymous : £50.00
  • elizabeth mayo : £50.00
  • Anonymous : £10.00
  • Punam Kaura : £150.00
  • janina inceman : £10.00
  • stephen ALGATE : £100.00
  • Neil Perry : £100.00
  • Steven Connors : £50.00
  • annick castel : £17.84
  • Alison Place : £20.00
  • David Kimis : £91.71
  • mohammad famili : £200.00
  • Anonymous : £15.00
  • Sandra Plange : £10.00
  • Dewi Kadarwati : £100.00
  • Anonymous : £32.22
  • Anonymous : £100.00
  • Marion & Martin Bodill : £20.00
  • Dorothy Bradshaw : £25.00
  • Anonymous : £100.00
  • Susan Willmott : £50.00
  • Aranka Kovacsevics : £20.00
  • Klaas and Anneke de Boer : £250.00
  • Dominique Laugel : £42.73
  • parmanand kassen : £30.00
  • Jai Campbell : £20.00
  • Feroz Ahmed : £100.00
  • Jimmy Hwang : £200.00
  • Anonymous : £90.00
  • Howard Wheeler : £10.00
  • Rupert Tan : £50.00
  • Anonymous : £150.00
  • Anonymous : £25.00
  • Jameel Bharmal : £50.00
  • Natasha Fonseka : £200.00
  • Anonymous : £40.00
  • Gordon Davies : £500.00
  • Amaya San Jose Legarreta & Maria Angeles San Jose Legarreta : £431.64
  • Darius Irani : £300.00
  • li lian lim : £1,000.00
  • Vasha & Rohit Raj : £50.00
  • Birgit Eichhorn : £20.00
  • Anonymous : £100.00
  • Nizwani Shahar : £15.32
  • Raja Nurmaria Murni Raja Nur Azmi : £15.36
  • Jasmini Alagaratnam : £30.00
  • Anand Krishna : £147.10
  • Richard Shepherd : £20.00
  • Patricia Schlagenhauf : £100.00
  • Mooji Foundation : £5,000.00
  • Anonymous : £50.00
  • Maren White : £100.00
  • Anonymous : £20.00
  • Diego A. Moreno : £25.00
  • Penny Tan : £100.00
  • Jonathan Tai : £100.00
  • Nicholas White : £200.00
  • Vanessa Toh : £100.00
  • Anonymous : £20.00
  • Anonymous : £50.00
  • Yeen Lei Chow : £100.00
  • Anonymous : £2,000.00
  • Sanjeev Krishna : £30.00
  • Mary Ann Augustin : £94.68
  • Andrew Johnston : £20.00
  • Praveen Nagappan : £47.28
  • Mita Kapila : £96.93
  • Patrick Zentler-Munro : £100.00
  • Sanjeev Krishna : £30.00
  • David Price : £100.00
  • Timothy Smith : £100.00
  • Bahariah Bahadom : £50.00
  • Paul J. Fitzpatrick : £100.00
  • Anonymous : £80.00
  • Enamul islam : £5.03
  • Steph Bennett : £27.33
  • Anonymous : £50.00
  • Raman Malhotra : £100.00
  • Anonymous : £1,000.00
  • Lillian Smith : £20.00
  • Anonymous : £50.00
  • Allison Coles : £20.00
  • Yoong Chuang Chow : £500.00
  • Anonymous : £100.00
  • Sarah Trigg : £10.00
  • Erik Miller : £30.00
  • Harriet Hayward : £10.00
  • Anonymous : £36.72
  • Rebecca Hood : £50.00
  • Penelope Laurenson : £50.00
  • Anonymous : £7.93
  • Elizabeth Thomsen : £15.00
  • Anonymous : £2.00
  • Anonymous : £2.00
  • Anonymous : £25.00
  • susan smith : £50.00
  • Kyla Wiggins : £50.00
  • Michelle Lee : £30.00
  • Anonymous : £369.60
  • Brian Malpass : £25.00
  • Baldev, Ash & Niraj Krishna : £2,000.00
  • Michael Wiggins : £99.02
  • Mohan Ramalingam : £100.00
  • Ted Ansusinha : £264.08
  • David Atkinson : £500.00
  • Katherine Barnett : £20.00
  • David Vesty : £1,000.00
  • David Ray : £100.00
  • Andrew Frankland : £40.00
  • Adrienne Lim : £20.00
  • Maciej Rychter : £50.00
  • INBA ABBRAHAM : £50.00
  • Emma Buchanan : £20.00
  • Beatrix Teo : £50.00
  • Sheraz Daya : £1,000.00
  • Feiko ter Kuile : £100.00
  • Nicole Tan : £14.93
  • Graham Archer : £20.00
  • Nerea Assan : £200.00
  • Sumana Perera : £100.00
  • Peter Baumgartner : £46.47
  • Robert Handley : £250.00
  • cathy jackson : £10.00
  • Ann Thompson : £40.00
  • William Ingham : £10.00
  • COLIN TURNBULL : £40.00
  • Anonymous : £20.00
  • Caroline Flatley : £20.00
  • Claire Hazeldine : £100.00
  • Mike Turner : £500.00
  • Mark Treherne : £100.00
  • Keith Archer : £200.00
  • Anonymous : £30.00
  • Anonymous : £25.00
  • Jean Hanmer : £10.00
  • Audrey Ngiam : £20.00
  • John Andrews : £10.00
  • Birgit Eichhorn : £15.00
  • mark james : £20.00
  • Diana Thomas : £50.00
  • John Page : £10.00
  • Amaya Assan : £250.00
  • Susan Wakelin : £30.00
  • Rhys Hedges : £5,000.00
  • Richard Mutton : £100.00
  • Shirley20 Sabin : £50.00
  • Anonymous : £20.00
  • William Morgan : £100.00
  • Anonymous : £100.00
  • Patricia Waters : £50.00
  • Michael Cain : £50.00
  • Colin Sinclair : £100.00
  • Anonymous : £20.00
  • Marian Clarke : £20.00
  • Ronald Rowson : £200.00
  • Anonymous : £10.00
  • Anonymous : £10.00
  • Gill Robson : £10.00
  • Anonymous : £20.00
  • Anonymous : £10.99
  • derek pryce : £20.00
  • John Gilson : £25.00
  • John Gilson : £20.00
  • Jo Hewitt : £25.00
  • Elaine Warburton : £500.00
  • Giles Nicklin : £25.00
  • John Beets : £100.00
  • Shirley Ellis : £50.00
  • GOZ LEE : £102.12
  • Sharif Assan : £100.00
  • Kevin Wiggins : £500.00
  • David Friend : £100.00
  • Kennath Pillay : £74.23
  • Mel Schmitz : £37.12
  • Keith Wiggins Wiggins : £10.00
  • Nafeesa Mat-Ali : £30.00
  • Adrian Camm : £10.00
  • Pauline Orchel : £20.00
  • Rosie onyett : £20.00
  • Rachel Holmes : £10.00
  • Anonymous : £200.00
  • Patricia Symons : £100.00
  • Anonymous : £50.00
  • Wendy Hancock : £20.00
  • RODNEY GILES : £30.00
  • Anonymous : £50.00
  • Anonymous : £25.00
  • Anonymous : £100.00
  • Anonymous : £25.00
  • H Laura Tattersall : £25.00
  • Mike Hawkes : £50.00
  • Anonymous : £25.00
  • Michael Hasler : £100.00
  • Paul Stone : £50.00
  • Anonymous : £20.00
  • Peter Leon : £200.00
  • Roger Bailey : £100.00
  • Catherine Wiggins : £10.00
  • Kristin Hartono : £50.00
  • Ian Mills : £100.00
  • Pamela Cross : £100.00
  • Anonymous : £10.00
  • Yoshie Shizusawa : £100.00
  • Denise Lin : £100.00
  • Anonymous : £200.00
  • Anonymous : £100.00
  • Martin Eaden : £25.00
  • Sue Flowerdew : £20.00
  • Alan Anderson : £100.00
  • James Arnell : £5,000.00
  • G W Corfield : £50.00
  • Vicky Hackett : £100.00
  • Anonymous : £50.00
  • Keith Ashworth : £50.00
  • Mrs K Scales : £100.00
  • Jamie yeow : £462.10
  • Betty Weill : £20.00
  • Michael Whitworth : £100.00
  • Clare Lindsay : £100.00
  • Anonymous : £30.00
  • Anonymous : £20.00
  • Anonymous : £25.00
  • Gillian Kerr : £50.00
  • Patricia Page : £50.00
  • Graham Haddow : £10.00
  • Andrew Cobner : £100.00
  • Jan McConnell-Wood : £25.00
  • panicos varnava : £10.00
  • Katie Foxall : £20.00
  • Kathryn Malpass : £25.00
  • Lisa Chaudhuri : £100.00
  • Robin Ketteridge : £100.00
  • Carmen van Rensburg : £50.00
  • Helen Church : £30.00
  • Yolanda and Marion Augustin : £100.00
  • Susan MacDonald : £20.00
  • Anonymous : £20.00
  • Anonymous : £100.00
  • Anonymous : £37.05
  • Anonymous : £100.00
  • Anonymous : £100.00
  • Anonymous : £25.00
  • Anonymous : £20.00
  • Anonymous : £15.00
  • Al Hynd : £5.00
  • Anonymous : £25.00
  • Susan Wiggins : £10.00
  • Anonymous : £100.00
  • Anonymous : £10.00
  • Anonymous : £10.00
  • Anonymous : £500.00
  • Alison Rose : £10.00
  • Bernd Reichert : £350.00
  • Deborah Waller : £30.00
  • Yin Wong : £30.00
  • Chun Fan Goh : £6.58
  • Arfon Jones : £500.00
  • David Clark : £20.00
  • Sapna Gadaria : £10.00
  • Sanjeev Krishna : £25.00
  • Richard Hooker : £100.00
  • Anonymous : £100.00
  • Gina Mascord : £9.20
  • Vincent Ang : £100.00
  • Ksenija Slavic : £10.00
  • Yoko Wada : £10.00
  • Mei Leng Yau : £10.00
  • Cathy Moore : £20.00
  • DEBORAH GERMAINE : £10.00
  • DAVID JEROME AUGUSTIN : £10.00
  • LUCILLE GERMAINE D'OLIVEIRO : £10.00
  • PHILOMENA MORRIS : £10.00
  • Patrick Cyril AUGUSTIN : £10.00
  • Helen Brownen : £91.18
  • Kirk family : £100.00
  • Arti Krishna : £35.00
  • Whitehouse Hebbourn Family : £500.00
  • Stanley Augustin / Sharif Assan : £100.00
  • Yolanda and Marion Augustin : £100.00
  • David Bateman : £500.00
  • Hajnalka Kovacsevics : £50.00
  • Charles Burton : £49.37
  • Tihana Bicanic : £30.00
  • Family Chiam : £25.00
  • Henry Staines : £25.00
  • Baldev, Ash & Niraj Krishna : £4,000.00
  • Anonymous : £1,000.00
  • Karim Krishna : £15.00
  • Anonymous : £15.00

Colorectal cancer is the 3rd most common cancer world-wide. There is an urgent need to improve survival rates. Our research is looking at whether we can use artesunate, an existing and safe anti-malarial drug, in a new way to improve survival from colorectal cancer. Repurposing established drugs to treat cancer in this way removes some of the delays and barriers faced when trying to develop effective new treatments.

 

Opens 22 September 2015 (Flexible Funding - this campaign will need to reach a minimum funding target of £5 000)

We are delighted to say that we can achieve the main objectives of our study with the funds raised up till now. We hope to raise additional funds that will now allow us to:

Recruit more patients by extending the study to partner hospitals. Crucially, this will enable us to complete the study and make the results available sooner.

Apply the latest molecular techniques to build on our understanding of how artesunate may work to kill cancer cells.

Develop collaborative studies with other countries, so that the benefits from artesunate use may be understood by the global medical community.

We thank all our donors for their exceptional support – it has been extraordinary to witness how their generosity has materialised from such diverse peoples and places. Our donors have also been the best peer-reviewers, because they have scrutinised our idea and found it worth backing – so many thanks once again. We have also been gratified by the thoughtful and interested comments made by so many people who have written to us, and by the interest in our approaches by the media as well as the platform (FutSci) that is supporting this work.

Our Campaign was recently featured on BBC news 'Campaign aims to fund new bowel cancer drug trial', please click on the link below:

http://www.bbc.co.uk/news/uk-england-london-34752388

This appeal is supported by:

                    

Colorectal cancer – the problem

Colorectal cancer is a leading cause of cancer related morbidity and mortality. There are more than one million new cases per year worldwide. Each day in the UK, 110 new colorectal cancer cases are diagnosed. Over half of new cases have locally advanced disease making recurrence more likely. Treating older patients is also more difficult and they are particularly at risk of dying from their disease.

Current treatments involve complex combinations of surgery, chemotherapy and radiotherapy. Unfortunately all these measures haven’t increased overall survival beyond 60%, 5 years after patients receive a diagnosis. We need new treatments urgently to improve survival rates. Developing new, effective drugs however can take many years and sometimes even decades.

Early treatment may improve patient survival rates

Giving treatments like chemotherapy before going onto surgery could be an important way to improve overall survival for patients. This could be for several reasons. Shrinking the tumour prior to surgery may increase the likelihood of successful complete surgical resection as well as reducing the risk of contamination of neighbouring areas during surgery. The delay between recovering from surgery and starting post-operative chemotherapy would be avoided and if microscopic areas of tumour have spread then these may also respond to treatment. A problem up till now though has been that chemotherapy has significant side effects. This usually means that surgery itself needs to be delayed until someone can recover from these effects. A treatment that didn’t delay surgery and was well-tolerated would be a major contribution to taking care of patients while they wait for their surgical treatment. It would also tell us how important to overall success early treatment might be. There would also be great added value if any treatment that worked was also cheap enough to be used almost everywhere in the world.

Artemisinins – the new aspirin?

Artemisinins like artesunate are used worldwide as part of the treatment for malaria. They come from a plant called sweet wormwood, and have been used for more than two millennia in traditional Chinese medicine. Ge Hong (281–340 AC) in his “Handbook of Prescriptions for Emergency Treatment” recommended tea-brewed leaves to be kept up the sleeve to treat fevers and chills, later sited by Li Shizen in 1596 in the “Compendium of Foundations of Materia Medica”. It is one of the most widely used antimalarial compounds having been used to treat tens of millions of adults and children globally. It is on the World Health Organisation's (WHO) list of essential medicines (WHO 2013).

Soon after their effectiveness against malaria was shown, studies started to confirm that artesunate could also kill cancer cells (Ho et al 2014). These studies have progressed quickly from work in the laboratory to observations made in individual patients and small clinical trials.

Repurposing drugs in Oncology

There is increasing interest in researching and repurposing existing, well established non-cancer drugs for new applications in oncology. Developing a new anti- cancer treatment can often take years to decades to go from the laboratory to clinic, and is often costly. Many new anti-cancer therapies remain out of economic reach for the majority of patients in developing countries where cancer incidence is increasing. If we are able to prove that an existing, well established drug such as artesunate has anti-cancer benefits in patients with colorectal cancer this would be a significant breakthrough- providing a low-cost, safe and effective treatment to meet the unmet needs of many cancer patients globally.

Our proposed clinical trial - Can Artesunate improve survival rates in Bowel Cancer?

We recently investigated and subsequently published a small but very informative study of oral artesunate treatment given to patients who were diagnosed with bowel cancer (Krishna et al 2015). In a small clinical pilot trial of 23 patients only 1 patient in the artesunate group had a recurrence of their cancer after 42 months, compared to 6 in the placebo group (those randomised to receive a non-active dummy pill). Patients were treated with oral artesunate daily for 2 weeks prior to surgical removal of their tumour.

We now need to do larger studies: to see if these encouraging results are confirmed.

We are committed to involving everyone more directly in medical research, because many people want to contribute in some way to cutting edge research but often cannot see where their contribution might end up.

Our study is designed to change practice in how we manage colorectal cancer, so if you think that this is important and worthwhile, we would very much value your involvement and contribution. For those who are interested in further details of the background to this work and the study we completed, some key references are attached.

We are launching this crowdfunding appeal to support study related costs such as academic trial sponsorship,conduct and data monitoring fees, research pharmacy fees, the cost of purchasing the study drug and matching placebo and the cost of conducting specialised molecular tests. Our minimum funding threshold to support this study is £5,000. Fifty thousand pounds will enable us to pay for academic trial sponsorship, conduct and data monitoring fees, pharmacy fees and drug costs. Additional funding beyond that will enable us to carry out specialised molecular testing to see if patients with particular tumour profiles may respond better to artesunate treatment.

 

Current chemotherapy treatments are associated with significant side effects and remain economically out of reach for the majority of patients in developing countries. There remains an urgent need to improve survival in patients with colorectal cancer globally.

Our research is investigating a means of developing a safe and affordable drug treatment for bowel cancer in the quickest possible time frame by re-purposing an existing anti-malarial drug, artesunate. The aim of our study is to see if a two week course of oral artesunate prior to surgery for bowel cancer can improve survival rates and reduce the risk of cancer coming back.

Clinical evidence of anti-tumour effects of Artesunate

We conducted the world’s first randomized, placebo controlled, double blind pilot study of artesunate in colorectal cancer.

Twenty-three patients suitable for surgery were randomised to receive either 14 daily doses artesunate or a placebo drug (no active drug). In the 42 months following treatment and surgery 6 patients in the placebo group had recurrence of their cancer whilst only 1 patient in the  artesunate group had a cancer recurrence. Artesunate was generally well tolerated.

These results  provided the basis for a larger Phase II clinical trial we are planning to carry out, investigating the effects of a two week course of artesunate in 140 patients with colorectal cancer prior to surgery.

References:

Ho WE, Peh HY, Chan TK, Wong WS.(2014) Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 142(1):126-39.

Krishna S, Ganapathi S, Ster IS, Saeed MEM, Cowan M, Finlayson C, Kovacsevics H, Jansen H, Kremsner PG, Efferth T, Kumar D.(2015) A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.  EBioMedicine 2(1): 82–90.

The socio-economic impact of Bowel Cancer worldwide

Worldwide, there are over 1 million cases of colorectal cancer diagnosed each year. Colorectal cancer is the third most common cancer in men and the second most common cancer in women and is a leading cause of morbidity and mortality. Regions with the highest incidence rates at present include North America, Australia, New Zealand, Europe, and Japan. There is an increasing incidence of colorectal cancer in lower income countries, with increasing mortality rates in countries in South America, Asia and Eastern Europe (From: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012).

Estimated global numbers of new cases and deaths with proportions by world regions, both sexes combined, 2012. The area of the pie is
proportional to the number of new cases or deaths

From: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Each day in the UK, 110 new colorectal cancer cases are diagnosed. There are currently around 244,000 people living with colorectal cancer in the UK (Macmillan 2014). Colorectal cancer is the second leading cause of cancer death in the UK, with over 15,000 people dying of colorectal cancer in 2011.Over 70% of colorectal cancers diagnosed between 2008-2010 were in people over the age of 65.

From: Global Cancer Facts and Figures: 2nd edition

By researching more effective treatments for colorectal cancer, we hope to decrease the suffering faced by many patients and their families. A drug that was relatively affordable compared to many existing anti-cancer treatments would also confer a significant economic benefit on healthcare systems around the world.

Our ability to carry out this clinical trial successfully is dependent on our ability to raise appropriate funds for molecular profiling tests that will help us personalise patient care

We currently have managed to raise part of the funding required,  through the charity Bowel Disease UK, to employ a full time clinical research fellow and cover the trial drug and trial monitoring costs. However we still need to raise funds for the molecular profiling tests we would like to conduct to give us greater insight into which patients may respond best to treatment and why, enabling us to adopt a more targeted therapy and personalised medicine approach to patient care. These molecular tests are expensive and thus success of this fund raising campaign is crucial to enable this important research to be conducted effectively and thoroughly.

References:

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray (2014). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer doi:10.1002/ijc.29210 PMID:25220842 Published online 9 October 2014

Macmillan Cancer Support (2014) The Rich Picture on people Living with Colorectal Cancer

Professor Sanjeev Krishna

I am Professor of Molecular Parasitology and Medicine at St George’s, University of London. After completing a science degree at the University of Cambridge and my medical degree at the University of Oxford, I studied malaria in Thailand before completing a DPhil at the Weatherall Institute of Molecular Medicine in Oxford. I joined St George’s Hospital NHS Trust as an Honorary Consultant in 1993. I was elected a Fellow of the Academy of Medical Sciences in 2004 and awarded a ScD by the University of Cambridge in 2007. I have had a special interest in the anticancer effects of antimalarial artemisinins for nearly a decade now and forged excellent multidisciplinary collaborations with respected colleagues and experts in colorectal surgery, cellular pathology and oncology. These collaborations resulted in our pioneering Phase I pilot study researching the effects of neoadjuvant artesunate in patients with colorectal cancer,which we published earlier this year. We  are committed to taking this research further with our planned Phase II study (NeoART), with the aim of improving survival and quality of life for millions of cancer patients globally.

Contact Details:

Tel: +44 (0) 208 725 5836

Email: s.krishna@sgul.ac.uk

Twitter @ProfSKrishna

Key Publications

Agnandji ST et al. (2015) Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report. N Engl J Med. Apr 1. 2015 DOI: 10.1056 [Epub ahead of print]

Lanini S et al. (2015) Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? Lancet Infect Dis.15(6):738-45.

Pinheiro MM et al. (2015) Plasmodium knowlesi genome sequences from clinical isolates reveal extensive genomic dimorphism. PLoS One.10(4):e0121303

Rolling T, Agbenyega T, Krishna S, Kremsner PG, Cramer JP. (2015) Delayed haemolysis after artesunate treatment of severe malaria - review of the literature and perspective. Travel Med Infect Dis.13(2):143-9.

Krishna S et al. (2014) A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. EBioMedicine 15;2(1):82-90

Rolling T et al. (2014) Delayed Hemolysis After Treatment With Parenteral Artesunate in African Children With Severe Malaria--A Double-center Prospective Study. J Infect Dis 209(12):1921-8.

Foster D, Cox-Singh J, Mohamad DS, Krishna S, Chin PP, Singh B. (2014) Evaluation of three rapid diagnostic tests for the detection of human infections with Plasmodium knowlesi. Malar J.13:60.

Zaloumis S et al. (2014) Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. Clinical Pharmacology and Therapeutics: Pharmacometrics and Systems Pharmacology. 3(11):1–9

Pulcini S et al. (2013) Expression in yeast links field polymorphisms in PfATP6 to in vitro artemisinin resistance and identifies new inhibitor classes. J Infect Dis. 208(3):468-78.

Tiberti N et al. (2013) Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness PLoS Negl Trop Dis.7(2):e2088

Kremsner PG et al. (2012) A simplified intravenous artesunate regimen for severe malaria. J Infect Dis.205(2):312-9.

Gravett AM et al. (2011) In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother Pharmacol. 67(3):569-77

Gomes MF et al. (2009) Pre-referral rectal artesunate to prevent death and disability in severe malaria: placebo-controlled trial. Lancet. 373:557–66. PMID: 19059639

Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A, Krishna S. (2008) Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis.8(12):777-84

Krishna S, Bustamante L, Haynes RK, Staines HM. (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci. 29(10):520-7

 

Dr Yolanda Augustin

Clinical Research Fellow

I am a registrar (junior doctor) in Clinical Oncology.I graduated from Guy's, King's and St Thomas’ Medical School, University of London, in 2004 with a MBBS and did a medical elective in oncology at the Mayo Clinic in Rochester, Minnesota. Following this I obtained a South London training number in Clinical Oncology and rotated through the Royal Marsden, Royal Surrey County and Guy's and St Thomas’ Hospitals, obtaining a Diploma in Oncology and FRCR (Fellow of the Royal College of Radiology).I have a special interest in colorectal cancer and research, looking at novel ways of improving patient survival, care and quality of life and am excited to be a part of this important and novel clinical study.

Publications and Posters:

Augustin YS, Birch M, Bodini C, Boulton F, Robertson E, Spada VM, Weingarten M. (2011) Prevention of torture by doctors and organisations. Lancet 378(9809):e22-3

Augustin YS ‘Buying Cake IS our job’, BMJ. 2007 335(7616): 379 PMCID: PMC1952492 *

Augustin YS, Anwar NI, McCoy D (2008) The Healthcare Sector :Prisoners’ In the Global Healthwatch Report 2: An Alternative World Health Report. London & New York :Zed Books*

Augustin Y, Tait D, Hawkins M (2012) Gastrointestinal Cancers Symposium, ASCO, United States Does phase I radiotherapy dose of 30.6Gy in 17 fractions provide adequate microscopic nodal disease control in squamous cell carcinoma of the anus?

British Endocrinology Society National Meeting, March 2009 The Management of Thyroid Fine Needle Aspiration (FNA) Cytology Samples Reported as Benign (Thy2): An Audit of Practice at a Teaching Hospital

International Palliative Care Conference organized by the European Association of Palliative Care in Budapest, June 2007. Audit of steroid prescribing in community palliative care patients with advanced cancer in East London

 

Hajnalka Kovacsevics

I am an experienced Administrative Coordinator who supports the conduct of clinical trials to cGCP standards as well as undertaking wider project management. This includes organising meetings, maintaining appropriate records (financial and scientific) related to projects and assisting in the preparation of reports. I also coordinate activities between SGUL and partners and I am fully conversant in financial aspects of project management and database technologies. I am trained as a nurse in Szigetvar (Hungary) after obtaining a scholarship from the Soros foundation.

Tel: + 44 (0) 208 725 0446

Email: hkovacse@sgul.ac.uk

Publications

Sanjeev Krishna, Senthil Ganapathi, Irina Chis Ster, Mohamed E.M. Saeed, Matt Cowan, Caroline Finlayson, Hajnalka Kovacsevics, Herwig Jansen, Peter G. Kremsner, Thomas Efferth, Devinder Kumar. A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. 15th Nov 2014, EBioMedicine 2 (2015) 82–90,

 

Rewards

£1 or more
Thank you for supporting us! Please tell your friends.

£5 or more 
We appreciate your support – Thank you! We’ll express our appreciation on Twitter or Facebook. Please help us spread the word!

£10 or more 
Thank you for being a Crowdfunder and lending us your support! You’ll receive a e-certificate endorsing you as a crowdfunder and our supporter. Help us spread the word!

£25 or more 
An Invitation to a webinar where you can find out more about the trial from Professor Krishna and his team. Thank you for supporting us!

£50 or more  
An Invitation to a lecture given by Prof Krishna discussing this research. You will have the opportunity to ask any questions you might have. Thank you!

£100 or more 
Thank you! An Invitation to a lecture given by Prof Krishna discussing this research. You’ll get to meet the researchers involved and have a tour around the lab. Please share our campaign!

£500 or more
You’ll be invited to a special afternoon tea party in late November 2015 to meet the researchers and discuss the project. We appreciate your support, please do share our appeal. 

£5000 or more
An Invitation for you and a partner to our special afternoon tea. You will also be acknowledged as a donor in our publications. Thank you once again for backing our appeal! 

 

Research Articles

Professor Sanjeev Krishna
Thank you very much to all our backers so far for your kind support!The response has been very encouraging. Please share this #Crowdfunding for #Cancer research project with friends,families and colleagues.We need everyone's help and participation to take this project foward.
28/09/2015 19:20:12
Professor Sanjeev Krishna
We were very pleased that an article was published in the Telegraph today on our Crowdfunding for Bowel Cancer research http://www.telegraph.co.uk/wellbeing/health-advice/pill-cancer-tumour-bowel-health-drugs-cheap/ We would like to thank all the patients involved in our Phase I study (and their families).The results from this study which we published earlier this year provided the basis for our next Phase II study for which we are now Crowdfunding.This work would not have been possible without your support and contribution.Thank you.
29/09/2015 09:24:19
Professor Sanjeev Krishna
Just received a very thoughtful email from a Crowdfunder: Dear Sir, I have just read in the Daily Telegraph about your inspirational research results on the potential benefits of artesunate in the treatment of bowl cancer. Your work sounds bold and inspired and intuitive and so down-to-earth and I am sure that there will be entire populations of future beneficiaries of your research who will be holding you in the greatest affection and esteem and so very deservedly. May blessings be on you and your colleagues, sent from a lay person who just has a very real curiosity and interest in the power of nature to help and heal when it is given the correct opportunities. So very many thanks and congratulations to you at St George's University in London. I hope distinctions and medals and funding will be given to you for your esteemed work.
29/09/2015 14:41:11
Professor Sanjeev Krishna
Phenomenal.We have raised 53% of our target in less than 9days!Truly amazing.Thanks so much to all our Crowdfunders for making this happen.Let's aim to raise the other 47% in the next 9 days!Here's to the ‪#‎POWER‬ of the ‪#‎CROWD‬!:) Please ‪#‎doitfightcancer‬
30/09/2015 21:58:06
Professor Sanjeev Krishna
When we first started this ‪#‎Crowdfunding‬ campaign for our Phase II clinical trial in bowel cancer we were not quite sure what to expect - and it certainly wasn't the phenomenal response we have seen in the past 9 days. We had heared of Crowdfunding platforms before for business,the arts and technology, but in the area of medical research and life sciences this seemed like quite a novel method of raising the funds needed for our planned research compared to the traditional grant application and pharma sponsored routes. We knew that we had an interesting and important research question and a decent amount of basic lab research in cancer cell lines to demonstrate biological plausibility for artesunate having anticancer effects.This led us to do the Phase I study of pre-operative artesunate in patients with operable colorectal cancer.Following our Phase I study results that we published in January this year we designed a larger Phase II study.We knew however that it would be unlikely to meet current mainstream funding criteria or receive pharmaceutical industry sponsorship. So that's when we turned to #Crowdfunding.The response has been truly phenomenal. In just 9 days we have managed to raise £26,499.93 from 158 backers. We have now reached over 50% of our intended goal of £50,000. Seeing the general public, patients and their families truly engage and back our study in such a generous way has been humbling and inspiring.Thank you for taking the time to back this project.We will send further progress updates on our campaign as we go along and of course future updates on the research project itself and our published findings. Please do not hesitate to get in touch with us should you have any questions. We now need to keep the momentum up to reach our target of £50,000. Please share with you friends,colleagues,contacts and networks!;) Thank you The NeoART trial Research team
01/10/2015 23:21:17
Sanjeev Krishna
So many backers have contributed already that it is genuinely gratifying to feel so supported - thanks again to all. Pass the word on and keep an eye on what we are up to - we will be updating regularly. Look forward to meeting up with some of you in due course.
04/10/2015 12:00:26
Professor Sanjeev Krishna
We have just reached the 2/3rd mark goal for our Crowdfunding Campaign!Thank you so much to all our generous backers.
06/10/2015 13:11:14
Sanjeev Krishna
More than 200 individuals have committed to this idea and we keep hearing of more who support - thanks for getting it and giving.
11/10/2015 10:29:54
Sanjeev Krishna
There is a large community working on repurposing drugs and the concept is being championed by Nick Thomas-Symonds Esq. MP for Torfaen in the shape of a Private Member's Bill. Artesunate for cancers is only one of many examples - see also Pan Pantziarka's lucid and closely reasoned arguments for repurposing in oncology (for an intro:http://www.theregister.co.uk/2015/03/08/drug_reuse_to_kill_cancer/) - we need a dedicated organisation to register drugs off-patent for off-label use - so that they then get used.
16/10/2015 16:00:12
Sanjeev Krishna
Robin Daly of 'Yes to Life' interviewed us (Yolanda and me) yesterday with questions that ranged across many areas related to crowdfunding, repurposing drugs and accelerating delivery of treatments for patients. The interview should become available in a couple of weeks for any interested in following up on these areas - I will keep posted also.
23/10/2015 09:00:00
Sanjeev Krishna
The off-patent Bill is discussed in yesterday's Telegraph piece that can be found here:http://www.telegraph.co.uk/news/health/news/11963655/Drugs-costing-pennies-could-help-those-with-breast-cancer-Parkinsons-disease-and-MS-experts-say.html
31/10/2015 09:24:01
Sanjeev Krishna
Robin Daly's (Yes To Life) interview broadcast tonight at 21:00 and then available at the Listen on Demand section at the bottom of this page: http://ukhealthradio.com/blog/program/yes-to-life-show
05/11/2015 16:55:33
Sanjeev Krishna
Many thanks to BBC London for bringing our efforts to wider attention: http://www.bbc.co.uk/news/uk-england-london-34752388
08/11/2015 11:45:20
Sanjeev Krishna
Our article on artesunate in ecancer is out for those interested: http://ecancer.org/journal/editorial/50-the-wisdom-of-crowds-and-the-repurposing-of-artesunate-as-an-anticancer-drug.php
12/11/2015 11:33:29
Professor Sanjeev Krishna
Thank you very much to all our backers for your fantastic support. We are happy to announce that clinical teams from additional NHS hospitals have now expressed an interest in recruiting to our study. This means that we may be able to achieve our recruitment target in a shorter period of time, providing important results more quickly. We are therefore stretching our fundraising goals to £75,000 to cover trial related costs at these additional sites. Please share this campaign with your friends, colleagues and families as we have just 10 days left to go. Every little helps. Your support is much appreciated.
17/12/2015 14:08:38
Login to post a comment